TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (‘Sosei’; TSE Mothers Index 4565), is pleased to note that our strategic minority investment company MiNA Therapeutics ('MiNA') has announced a collaboration and licensing agreement with the global pharmaceutical company Boehringer Ingelheim for the development of novel treatment approaches for fibrotic liver diseases.
Under the terms of the agreement, MiNA will receive an upfront payment and committed research funding as well as potential research, development and regulatory milestone payments totaling up to EUR 307 million. In addition, MiNA is entitled to double-digit royalties on sales of selected products resulting from the partnership. No further financial details were disclosed.
Commenting on the release, Peter Bains, CEO at Sosei, said: “We are very encouraged by this agreement, which is MiNA’s first ever major collaboration and reinforces its leading position in small activating RNA (‘saRNA’) therapeutics. Furthermore, we believe it represents a strong validation of the broad potential for its proprietary technology.”
Click here for link to the full press release from MiNA Therapeutics and Boehringer Ingelheim
About Sosei Group Corporation
Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei has established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei has already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.
For further information about Sosei, please visit http://www.sosei.com/en/.
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.